Accord Healthcare has launched an app to support cancer patients and help manage symptoms, incorporating expert data from Macmillan Cancer Support.
Accord Healthcare has launched the Unify Health digital app to support cancer patients and help them to manage their symptoms, in part using information from the UK’s Macmillan Cancer Support charity.
Digital healthcare is a key area of focus within the value-added medicines sector, as companies look to innovate around patient...
A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.
This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.
In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.
Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.
The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.
Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.
